Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Case Report

Published on 25 Apr 2025

Case report: Transformative potential of trastuzumab deruxtecan in the first line treatment for advanced HER2-mutated lung adenocarcinoma: a case report and clinical insights

in Pharmacology of Anti-Cancer Drugs

Guanbin Huang
Tongtong Xia
Dongxiao Yang
Muwen Lin
Yiping Luo
Yuchan Li
Hualin Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1564834

1,250 views

Mini Review

Published on 24 Apr 2025

Research progress on ferroptosis and PARP inhibitors in ovarian cancer: action mechanisms and resistance mechanisms

in Pharmacology of Anti-Cancer Drugs

Jiqing Zhang
Dan Ouyang
Mu Liu
Yuting Xiang
Zhongjun Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1598279

1,428 views

Original Research

Published on 24 Apr 2025

Bioactive natural alkaloid 6−Methoxydihydrosanguinarine exerts anti−tumor effects in hepatocellular carcinoma cells via ferroptosis

in Pharmacology of Anti-Cancer Drugs

Linfen Han
Chengchang Gao
Xiaorui Jin
Yingping Li
Liangjie Chen
Donglin Li
Qinqin Deng
Xueli Bian

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1500461

966 views

Correction

Published on 23 Apr 2025

Corrigendum: Synthesis, characterization, and computational evaluation of some synthesized xanthone derivatives: focus on kinase target network and biomedical properties

in Pharmacology of Anti-Cancer Drugs

Wisam Taher Muslim
Layth Jasim Mohammad
Munaf M. Naji
Isaac Karimi
Matheel D. Al-Sabti
Majid Jabir
Mazin A. A. Najm
Helgi B. Schiöth

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1583894

568 views

Original Research

Published on 22 Apr 2025

Adverse reactions of four multi-targeted tyrosine kinase inhibitors: a descriptive analysis of the WHO-VigiAccess database

in Pharmacology of Anti-Cancer Drugs

Lijun Li
Jiayu Bai
Xuelong Wen
Xuefan Zeng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1585862

907 views

Original Research

Published on 22 Apr 2025

RNF180 weakened the lipid droplet formation and subsequent chemoresistance by destabilizing ACC1 and ACLY in esophageal cancer

in Pharmacology of Anti-Cancer Drugs

Ning Li
Dao-Fu Shen
Nan-Chang Yin
Zheng-Guo Cui
Hua-Chuan Zheng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1525431

1,346 views

Original Research

Published on 17 Apr 2025

LINC01559 drives osimertinib resistance in NSCLC through a ceRNA network regulating miR-320a/IGF2BP3 axis

in Pharmacology of Anti-Cancer Drugs

Leidi Xu
Yibo Zhang
Liangliang Xing
Ying Zhou
Ning Chang
Hangtian Xi
Xiangrui Xu
Jian Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1592846

1,076 views

Original Research

Published on 17 Apr 2025

Targeting PCNA/PARP1 axis inhibits the malignant progression of hepatocellular carcinoma

in Pharmacology of Anti-Cancer Drugs

Jipin Li
Tao Yong
Yali Chen
Tingyu Zeng
Kaifeng Zhang
Shuping Wang
Youcheng Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1571786

932 views

Review

Published on 16 Apr 2025

SREBP2 as a central player in cancer progression: potential for targeted therapeutics

in Pharmacology of Anti-Cancer Drugs

Ruiqi Chen
Tianyu Chen
Xiang Li
Junfeng Yu
Min Lin
Siqi Wen
Man Zhang
Jinchi Chen
Bei Yi
Huage Zhong

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1535691

1,244 views

Original Research

Published on 16 Apr 2025

SUMOylation substrate encoding genes as prognostic biomarkers in pancreatic ductal adenocarcinoma with functional assessment of SAF-B2

in Pharmacology of Anti-Cancer Drugs

Xiangjun Wang
Chuanxin Yang
Yangming Liu
Jian Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1532658

1,004 views

Editorial

Published on 16 Apr 2025

Editorial: Multi-omics application in exploring potential biomarkers targeting resistance of anti-cancer drugs

in Pharmacology of Anti-Cancer Drugs

Huan Wang
Jindong Xie
Zhi Tian
Diane S. Allen-Gipson
Hailin Tang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1594064

1,047 views

Original Research

Published on 16 Apr 2025

Synthesis of a novel mitochondrial fluorescent probe - killing cancer cells in vitro and in vivo

in Pharmacology of Anti-Cancer Drugs

Xiaowen Yang
Yiting Zhan
Yifei Li
Xinzhuang Shen
Yuqiu Ma
Zongjun Liu
Yipeng Liu
Chengjin Liang
Xiaoyuan Zhang
Yehao Yan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1543559

1,023 views

Editorial

Published on 16 Apr 2025

Editorial: Autophagy and lung cancer therapy: targeted drug development and new emerging technology

in Pharmacology of Anti-Cancer Drugs

Ming Zhang
Yu Wang
Chunhui Yang
Xin You
Yafei Feng
Xianglin Yang
Qi Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1599548

778 views

Original Research

Published on 15 Apr 2025

Multiscale screening and identifying specific targets for artesunate in suppressing bladder cancer

in Pharmacology of Anti-Cancer Drugs

Yi Yuan
Guangdi Chu
Qingyue Ma
Zhijuan Liang
Ye Liang
Haitao Niu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1584502

1,146 views

Review

Published on 15 Apr 2025

Parthenolide: pioneering new frontiers in hematological malignancies

in Pharmacology of Anti-Cancer Drugs

Elmira Zarei
Ayda Zarei
Azadeh Omidkhoda

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1534686

972 views

Original Research

Published on 15 Apr 2025

Integrative analysis of m6A-SNPs and single-cell RNA sequencing reveals key drivers of endocrine combined with CDK4/6 inhibitor therapy resistance in ER+ breast cancer

in Pharmacology of Anti-Cancer Drugs

Ruijie Ming
Han Zhang
Huan Wu
Fangbiao Zhan
Xiaoping Huang
Huawen Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1590363

1,143 views